Atazanavir: A new protease inhibitor to treat HIV infection

American Journal of Health-System Pharmacy

Volumn 61, Issue 13, 2004, Pages 1365-1374

  Musial, Bogdan L ^a   Chojnacki, Joanna K ^a   Coleman, Craig I ^b,c,d  

^a Veterans Administration Healthcare System   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c HARTFORD HOSPITAL   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Antiretroviral agents; Atazanavir; Combined therapy; Drug interactions; Formularies; HIV infections; Mechanism of action; Pharmacokinetics; Resistance; Ritonavir; Saquinavir; Toxicity

Indexed keywords

AMPRENAVIR; ATAZANAVIR; ATENOLOL; CLARITHROMYCIN; DIDANOSINE; DILTIAZEM; EFAVIRENZ; ETHINYLESTRADIOL; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; RIFABUTIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE; OLIGOPEPTIDE; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE;

CLINICAL TRIAL; DRUG RESISTANCE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; JAUNDICE; LIPID METABOLISM; LYMPHOCYTE COUNT; MUTATION; NAUSEA; PRIORITY JOURNAL; RASH; REVIEW; VIRUS LOAD; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1;

CLINICAL TRIALS; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; OLIGOPEPTIDES; PYRIDINES; SAQUINAVIR;

EID: 5144225240     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.13.1365     Document Type: Review

References (40)

1. Center for Disease Control and Prevention. HIV/AIDS surveillance report. www.cdc.gov/hiv/stats/hasrlink.htm (accessed 2003 Jul 12).
2. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (November 2003). http:// AIDSinfo.nih.gov/guidelines/adult/ AA_111003.pdf (accessed 2004 Mar 31).
3. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997; 337:725-33.
4. Vittinghoff E, Scheer S, O'Malley P et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis. 1999; 179:717-20.
5. Richman DD, Bozzette S, Morton S et al. The prevalence of antiretroviral drug resistance in the US. Paper presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2002 Dec.
6. Bartlett JA. Addressing the challenges of adherence. J Acquir Immuno Defic Syndr. 2002; 29(suppl 1):S2-10.
7. Bartlett JA, Demasi R, Quinn J et al. Overview of the effectiveness of triple combination therapy in anti-retroviral naïve HIV-1 infected adults. AIDS. 2001; 15:1369-77.
8. Wanke CA, Falutz JM, Shevitz A et al. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis. 2002; 34:248-59.
9. Reyataz (atazanavir sulfate) package insert. Princeton, NJ: Bristol-Myers Squibb; 2003 Jun.
10. Dickerson K, Scherer R, Lefebvre C. Systematic reviews: identifying relevant studies for systematic reviews. BMJ. 1994; 309:1286-91.
11. Robinson B, Riccardi K, Gong Y et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother. 2000; 44: 2093-9.
12. Sweetman S, ed. Martindale: the complete drug reference. London: Pharmaceutical Press. Electronic version, MICROMEDEX, Greenwood Village, CO, Edition expires 9/2003.
13. Colonno R, Thiry A, Limoli K et al. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother. 2003; 47:1324-33.
14. Miller V. Resistance to protease inhibitors. J Acquir Immune Defic Syndr. 2001; 26(suppl):S25-33.
15. Schnell T, Schmidt B, Moschik G et al. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples. AIDS. 2003; 17:1258-61.
16. O'Mara EM, Smith J, Olsen SJ et al. Single and multiple oral dose safety and pharmacokinetic study in healthy volunteers. Paper presented at 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL; 1999.
17. Omara E, Mummaneni V, Randall D et al. BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects. Paper presented at 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
18. Sanne I, Piliero P, Squires K et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. J Acquir Immune Defic Syndr. 2003; 32:18-29.
19. Sanne I, Cahn P, Percival L et al. Comparative results (phase II 48-week): BMS-232632, stavudine, lamivudine as HAART for treatment-naïve HIV(+) patients (AI424-008). Paper presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 2002 Dec.
20. Murphy R, Pokrovskiy V, Rozenbaum W et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS study 008/044. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003 Feb.
21. Haas D, Zala C, Schrader S et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS. 2003; 17:1339-49.
22. Squires KE, Thiry A, Giordano M. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed dose ZDV + 3TC: comparison of antiviral efficacy and safety through week 24 (AI423-034). Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA; 2000 Sep.
23. Nieto-Cisneros L, Zala C, Fessel WJ et al. Antiviral efficacy, metabolic changes and safety of atazanavir (ATV) versus lopinavir/ritonavir (LPV/RTV) in combination with 2 NRTIs in patients who have experienced virologic failure with prior PI-containing regimen(s): 24-week results from BMS AI424-043. Antivir Ther. 2003; 8(suppl 1):S212. Abstract.
24. Badaro R, DeJesus E, Lazzarin A et al. Atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) vs. lopinavir/ ritonavir (LPV/RTV) in patients with multiple virologic failures: 24 week results from BMS AI424-045. Paper presented at 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France; 2003 Jul.
25. Food and Drug Administration. Atazanavir (BMS-232632): FDA advisory committee briefing document. www.fda. gov/ohrms/dockets/ac/03/briefing/ 3950B1_01_BristolMyersSquibb-Atazanavir.pdf (accessed 2003 Jul 20).
26. Food and Drug Administration. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval. October 1999. www.fda.gov/cder/guidance/3647fnl.pdf (accessed 2004 Mar 31).
27. Omara E, Randall D, Passarell J et al. Population pharmacodynamic assessment of atazanavir exposure, uridine diphosphate-glucuronosyl transferase (UGT) 1A1 genotype and safety in healthy subjects. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 2000 Sep.
28. Piliero P, Cahn P, Pantaleo G et al. Atazanavir: a once daily protease inhibitor with a superior lipid profile: results of clinical trials beyond week 48. Paper presented at 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2002 Feb.
29. Randall M, Agarwala S, Mummaneni V. Multiple-dose pharmacokinetics of atazanavir in healthy subjects: a summary of food effect and drug interaction studies. Paper presented at 42nd International Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 2000 Sep.
30. Preston S, Piliero P, O'Mara E et al. Evaluation of steady-state interaction between atazanavir (ATV) and efavirenz (EFV). Paper presented at 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2002 Feb.
31. Tackett D, Child M, Agarwala S et al. Atazanavir: a summary of two pharmacokinetic interaction studies in healthy subjects. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003 Feb.
32. O'Mara E, Agarwala S, Randall D et al. Steady state pharmacokinetic interaction study of atazanavir (ATV) with efavirenz (EFV) and ritonavir (RTV) in healthy subjects. Paper presented at 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2002 Feb.
33. O'Mara E, Randall D, Mummaneni V et al. Steady state pharmacokinetic interaction study between BMS-232632 and ketoconazole in healthy subjects. Paper presented at 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 2000 Sep.
34. Agarwala S, Mummaneni V, Randall D et al. Pharmacokinetic (PK) effect of rifabutin (RIF) on atazanavir (ATV) with and without ritonavir (RTV) in healthy subjects. Paper presented at 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2002 Feb.
35. Agarwala S, Russo R, Mummaneni V et al. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 2000 Sep.
36. Mummaneni V, Randall D, Geraldesi H et al. Steady-state pharmacokinetic (PK) interaction of atazanavir (ATV) with lamivudine (3TC) and zidovudine (ZDV) in healthy subjects. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 2000 Sep.
37. Taburet AM, Piketty C, Gerard L et al. Pharmacokinetic parameters of atazanavir/ritonavir when combined with tenofovir in HIV infected patients with multiple treatment failures: a substudy of puzzle 2-ANRS 107 trial. Paper presented at 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003 Feb.
38. Cardinal Health. www.cardinal.com (accessed 2003 Sep 17).
39. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133:21-30.
40. Dube MP, Sprecher D, Henry WK et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis. 2000; 31:1216-24.